Summary
March 3, 2025 | 11:30 AM – 2:30 PM ET
Presented by the Lyceum Society
Welcome and Introductions: 11:30 AM to 11:45 AM
Initial Presentation: 11:45 AM to 12:45 PM
25th Anniversary of the 9/11 Terrorist Event
David J. Haas
Because of the 9/11 terrorist events, our federal, state and local governments have instituted many improvements for the safety and security of the United States. This presentation will discuss these changes and explain how all citizens of the United States (as well as citizens worldwide) are safer and have improved travel safety.
Most of these improvements have been the result of the published “9/11 Committee Report” (July 2004). Almost all the recommendations of the report were implemented, including the formation of the Department of Homeland Security and the Transportation Security Administration. While there have been no US aircraft hijacked or destroyed since 2001, hundreds of guns are captured from passengers each year at US airports. These security measures will be with us forever.
Main Presentation: 12:45 PM to 2:30 PM
Ferroptosis and Cuproptosis: Cell Death Mechanisms in Pathogenesis and Therapeutics
Clif Hotvedt
Numerous mechanisms have been identified as participating in programmed cell death, including apoptosis, necroptosis, pyroptosis, and autophagy. (They will be summarized.) Two recently characterized mechanisms—ferroptosis and cuproptosis—iron and copper-related forms of cell death, respectively—have been associated with disease causation, e.g., neurodegenerative diseases such as epilepsy, Alzheimer’s disease, Parkinson’s disease and amylotrophic lateral sclerosis (ALS, Lou Gherig’s disease) and disease therapy (e.g., rheumatoid arthritis, various cancers). This presentation will address both aspects of these mechanisms as well as the rationale for possible therapeutic approaches.
Speakers
Clif Hotvedt’s diverse scientific background reflects his experience in the pharmaceutical industry, as a medical writer in the regulatory and clinical affairs departments of Ives Laboratories and at leading public relations firms including Robert Marston & Associates, Manning Selvage & Lee, and Ketchum, where he served as vice president and global director of medical & scientific affairs. For 46 years, he has counseled companies on over 100 small molecule drugs, biologicals and devices for indications including cardiovascular disease, rheumatology, metabolic disease, dermatology, central nervous system disease, vaccines, infectious disease, and cancer.
A New Mexico State University graduate in secondary education and journalism, Clif continues to use his teaching background to develop and present courses on the FDA approval process, pharmacokinetics, pharmacodynamics, and biostatistics among other topics for coworkers and clients. Clif is a member of the Lyceum Society and has been a frequent presenter at our meetings. His previous topics have included: “The FDA Drug Approval Process”(November 2015); “How the new PCSK9 Cholesterol-Lowering Drugs work” (May 2016); “How to read a Drug Label” (April 2017); “Biosimilars: the New ‘Generics’?(June 2018); “The Human Microbiome” (May 2019); “Drug Pricing” (June 2020); “Artificial Intelligence (AI) and Health Care” (October 2020); “Drug Pricing Revisited” (November 2020); and “The Nobel Prize in Physiology or Medicine 2022” (December 2022).
David Haas received his BA in Physics and PhD in Biophysics in protein crystallography and molecular biology at the State University of NY at Buffalo. For the next five years, he performed basic research in protein crystallography at several institutions in Europe, Israel and the United States. In 1970, he joined Philips Electronic Instruments in Mt Vernon NY as Principal Scientist for X-ray systems, working on analytical instruments and designing some of the first airport security X-ray systems that were used worldwide during the 1970s. Conceiving the idea of a self-expiring security ID (Visitor badge), David and his wife, Sandra, formed Temtec Inc. which developed and manufactured high-tech visitor and temporary IDs for more than 20 years under the brand name TEMPbadge. Temtec Inc. was sold to Brady Worldwide Corporation in 2002. David & Sandra Haas have more than 100 patents to their credit as well as many technical and scientific publications.
Dr. Haas has published a book by ASIS International entitled: “Personal Identification – Its Modern Development and Security Implications.” It reviews the history and reasons for modern personal identification documents such as Passports, National Identity Cards, etc. Dr. Haas has also published a monograph on the development of Electronic Security Screening for Aviation Passenger Screening between 1968-1973.
Pricing
All: Free
About the Series
The Lyceum Society is a collegial venue promoting fellowship, education, and discussion among retired members of NYAS. Learn more and explore other events hosted by the Lyceum Society.
Registration
Registration has closed.